ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Rituximab therapy in adults with steroid-dependent nephrotic syndrome

Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Weng, Wenjuan南方医科大学; 汕头大学
Archives of Medical Science2023DOI: 10.5114/aoms.2019.88404
7阅读
引用收藏
分享

摘要

Introduction: Patients with steroid-dependent nephrotic syndrome (SDNS) suffer frequent relapse with adverse effects caused by long-term predniso-lone treatment. Recently, the chimeric monoclonal antibody against the pro-tein CD20 (rituximab - RTX) was observed to be efficacious and safe in the treatment of patients with SDNS. We summarized the scientific literature to evaluate RTX therapy in the clinical management of SDNS.Material and methods: PubMed, EMBASE, and Cochrane Library databases were investigated from interception to 2019-6-6, without language limita-tion. The analysis was restricted to adults & GE; 19 years of age. Data were ad-ministered and analyzed through the Review manager 5.3 software.Results: After RTX treatment, relapse times, prednisolone dose, and protein-uria decreased, whereas serum albumin was increased. The clinical param-eters blood pressure and total cholesterol diminished also, whereas bone mineral density was improved. Overall, RTX ameliorated the adverse effects of prednisolone. Moreover, the Th1/Th2 ratio was changed except for the CD19 and CD20 cell counts. Additionally, most of the adverse effects of RTX were mild and well tolerated.Conclusions: In the studies that we considered, we concluded that RTX treatment was effective and safe in the therapy of patients with SDNS. Nevertheless, more randomized controlled trials are required to explore the mechanism of RTX action and verify its efficacy.

学科与关键词

关键词
steroid-dependent nephrotic syndromerituximabefficacysafety
相关
加载中…
  • Rituximab for the treatment of idiopathic membranous nephropathy with nephrotic syndrome: a systematic review and meta-analysis
    You, Lu; Ye, Peiyi; Xiao, Guanqing; Liang, Jiabao; Kong, Yaozhong*Turkish Journal Of Medical Sciences, 2021, 51(6): 2870-2880.被引 2
  • Extended infusion of rituximab combined with steroids is effective in inducing remission and reducing relapse in adult minimal change disease
    Liu, Diankun; Zhou, Zhanmei; Wang, Mengyi; Nie, Sheng; Li, Jun; Hu, Bianxiang; He, Wenjuan; Wang, Guobao*; Ai, Jun*BMC Nephrology, 2021, 22(1): 242.
  • Clinical efficacy and safety of rituximab with membranous nephropathy: a meta-analysis
    Zhong, Hongzhen; Li, Hong-Yan; Zhou, Tianbiao*; Zhong, ZhiqingArchives of Medical Science, 2023, 19(2): 411-419.
查看全部 →

发表信息

论文状态
公开发表
期刊
Archives of Medical Science
发表日期
2023
卷期
第 19 卷, 第 3 期
页码
577-585
DOI
10.5114/aoms.2019.88404
语言
ENGLISH
成果收录
SCIE

作者

  • Z

    Zhong, Hongzhen (第一作者)

    2 · shantou univ

  • L

    Li, Hong-Yan

    southern med univ

查看全部 4 位作者收起作者
  • Z

    Zhou, Tianbiao (通讯)

    2 · shantou univ

  • W

    Weng, Wenjuan

    2 · shantou univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417